目的：了解我院住院患者华法林的应用情况，为规范其临床应用提供参考。方法：调取我院2013 年1 月－2014 年6 月应

用华法林的住院病历267 份，对华法林临床应用的适应证、用药剂量、国际标准化比值（INR）监测、出血并发症等进行系统的回顾

性调查分析。结果：我院华法林主要应用于深静脉血栓、脑梗死、风湿性心脏病及肺栓塞患者等；住院患者华法林用量范围为

0.625～6.875 mg，平均日剂量（2.15±0.72）mg；INR＜1.8 的病例占52.8％，INR 在1.8～3.0（达标）的病例占31.8％，INR＞3.0 的病

例占15.4％；华法林总不良反应发生率为5.6％，主要为皮下淤点（淤斑）和尿潜血，严重出血（脑出血）发生率为0.7％。结论：目前

华法林临床应用仍不够规范，INR达标率偏低，积极开展华法林用药干预和临床药学监护具有重要意义。

OBJECTIVE：To investigate the clinical application of warfarin in inpatients of our hospital，and provide reference

for standardized application in clinic. METHODS：Totally 267 inpatients records used warfarin in our hospital from Jan. 2013 to

Jun. 2014 were investigated to retrospectively analyze the indications，dosage，international normalized ratio（INR）monitoring and

bleeding complications of warfarin. RESULTS：Warfarin was mainly used for patients with deep vein thrombosis，cerebral infarction，

rheumatic heart disease and pulmonary embolism in our hospital；the dosage of inpatients was in the range of 0.625-6.875 mg

with average daily dosage of（2.15 ± 0.72）mg；the INR lower than 1.8 accounted for 52.8％ ，the INR in the range of 1.8-3.0

（reaching the standard）accounted for 31.8％ and INR higher than 3.0 accounted for 15.4％；incidence of adverse reactions was

5.6％ ，mainly subcutaneous blood spots （petechiae） and urine occult blood，and incidence of severe hemorrhage （intracerebral

hemorrhage）was 0.7％. CONCLUSIONS：At present，the clinical application of warfarin is still deficient，and qualified rate of

INR is still low. It’s important to actively carry out medication intervention and clinical pharmaceutical care.